Allergan has declined to say one way or the other whether it is the end of the road for abicipar pegol, the company's troubled potential new treatment for neovascular (wet) age-related macular degeneration (AMD).
There is an expectation that Allergan parent AbbVie Inc. will ditch the ophthalmic candidate in the wake of...








